title: Immunotherapy of superficial bladder tumors: preliminary results with ImmuCyst--BCG Connaught, Toronto.
abstract: A clinical study has been started in 1991 with ImmuCyst (BCG Connaught) as a secondary prophylaxis in urothelial superficial bladder tumors (SBT) patients. Till now 31 patient have been entered into the trial and the results seem to be promising. Only 2 patients were excluded from the study. Side-effects did not extend in average the data quoted in literature and were easily managed. There were 4 recurrences confirmed by cystoscopy. Urinary infection was treated in 7 cases with current chemotherapeutic drugs.
authors.affiliation: Urocentrum CK, Prague, Czech Republic.
authors.forename: M
authors.initials: M
authors.lastname: Hanus
authors.forename: M
authors.initials: M
authors.lastname: Matousková
authors.forename: P
authors.initials: P
authors.lastname: Verner
authors.forename: L
authors.initials: L
authors.lastname: Hyrsl
mesh_terms: D000328:Adult; D000368:Aged; D001500:BCG Vaccine / Q000009:adverse effects / Q000627:therapeutic use*; D005334:Fever / Q000209:etiology; D006417:Hematuria / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
chemical_list: C087507:BCG Connaught; D001500:BCG Vaccine